Value Investing News

JNJ the best of Pharma

the best of pharma - Johnson & Johnson valuation compared against, Celgene, Pfizer, Abbott Laboratories, Merck and Bristol Myers Squibb

Christmas is a time of giving. Families and loved-ones give gifts to each other. Many people give money to the needy and charities. It seems that everyone is involved in giving this time of year, even corporations. Dividend growth stocks give a gift that keeps on giving – ever increasing dividends!

This real special situations investment account was up 2.8% in November and the year-to-date performance for the portfolio remains a strong 45.35%. Read about the latest transactions involving Western Sizzlin, Steak n Shake, Centennial Communications, and Bristol-Myers Squibb.

Screening the Modern Graham valuation database for the 10 highest dividend yields suitable for enterprising investors.

Sequoia's Q3 portfolio has been filed. New or increased positions include: AAP, PX, AOC, EOG, CACC, BDX, LTR, CB, BMY, CHK, BER, DHR, WMT, PG, V, JNJ, KFT, etc.

Screening the Modern Graham valuation database for companies suitable for the enterprising investor. These ten companies are among the highest dividend yields in the database.

ModernGraham's Dividend Portfolio made up of the top 10 dividend yields in the site's valuation database.

Their is no limit to the tools that can be found for technical analysis, but when it comes to fundamental analysis I seem to always find myself staring at raw numbers on a balance sheet. So I started building one- have a look and let me know what you think.

This week we are reviewing Bristol-Myers Squibb as a possible stock acquisition. To do so we will use the Buffett four filters we discussed in a previous article.

Abbott Laboratories manufactures and sells health care products worldwide.
The companyis a component of the S&P 500 and is a dividend aristocrat, which has been consistently increasing its dividends for 37 consecutive years. Most recently Abbott raised its quarterly dividend payment by 11% to $0.40/share.

Fairholme Fund's Bruce Berkowitz latest holdings.

There has been a lot of strong recommendations around biotech lately on Contrarian Profits. Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.

Another strong play from medical stock expert Rob Fannon.

The biotech industry has failed in its attempt to function as a science-based business